RESP301
Phase 2/3- Indications
- Bronchiectasis, Non-cystic fibrosis bronchiectasis
Company intelligence / Profile preview
Thirty Respiratory Limited
London, Greater London, United Kingdomfind-and-update.company-information.service.gov.uk ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 3
01
Overview
Currently conducting multiple Phase 2 clinical trials for respiratory infections. Has completed a Phase 2 trial for tuberculosis treatment and has active trials for non-cystic fibrosis bronchiectasis with Pseudomonas aeruginosa and other potentially pathogenic microorganisms.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Nitric oxide-generating technologies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Thirty Respiratory Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thirty Respiratory Limited.